Abstract

Chronic venous insufficiency (CVI) describes a condition that affects the venous system of the lower extremities, with an essential condition being persistent ambulatory venous hypertension casing various pathologies, including pain Oedema, skin changes and ulceration.1-3 Reports of prevalence of chronic venous insufficiency vary from < 1% to 40% in females and from < 1% to 17% in males. Prevalence estimates for varicose veins are higher, <1% to 73% in females and 2% to 56% in males.4 The manifestations of CVI may be viewed in terms of a well-established clinical classification scheme. The Clinical, Ethology, Anatomic, Pathophysiology (CEAP) classification was developed by an international consensus conference to provide a basis of uniformity in reporting, diagnosing, and treating CVI .5 Diagnostic modalities for Chronic venous sufficiency include duplex ultrasound scanning which is gold standard and first diagnostic testi. It is found to be over 98% sensitive and 93-97%.6 Micronized purified flavonoid fraction (MPFF) is a flavonoid-based venoactive drug, and is the only venoactive drug to demonstrate significant anti-inflammatory and venoprotective actions, which distinguishes this drug from other venoactive drugs to provide patients with rapid and substantial relief of symptoms. MPFF also provides a unique protection against complications by preserving the venous valves and walls

Description